Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Altria Group (MO) Misses Q2 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference
January 7, 2019 7:00 AM ESTMulti-franchise strategy ongoing in depression, neurology and neuropsychiatry
Commercial infrastructure build completed for ZULRESSO (brexanolone) injection ahead of March 19, 2019 target PDUFA date
Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum depression
First patient dosed in second pivotal trial of SAGE-217 in major depressive disorder
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer,... More
Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression
January 7, 2019 6:00 AM ESTStatistically significant reduction observed in depressive symptoms compared to placebo in women with postpartum depression (PPD)
Well-tolerated with rapid onset of statistically significant effect (Day 3) through two weeks and maintained for four weeks after treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient... More
